Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 11Breast 8Thoracic 2Sarcoma 2Head & Neck 2Genitourinary 2Gynecologic 1

Conditions

Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 180Cisplatin 157Radiotherapy 78Carboplatin 71Radiotherapy, Intensity-Modulated 69Cetuximab 66Magnetic Resonance Spectroscopy 64Nivolumab 63Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 35Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27toripalimab 26Drug Therapy 26Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22atezolizumab 21Capecitabine 20Ipilimumab 19Chemoradiotherapy 19durvalumab 18Taxes 17Immune Checkpoint Inhibitors 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
zanidatamab × Head & Neck × 1 year × Clear all
NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Jazz Pharmaceuticals

Phase 2 Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07192068 2025-12-19

AcSé HER2

UNICANCER

Phase 2 Recruiting
105 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡